221 related articles for article (PubMed ID: 35366569)
1. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N; Sikic D; Saal J; Büttner T; Goldschmidt F; Jarczyk J; Becker P; Zeuschner P; Weinke M; Kalogirou C; Breyer J; Burger M; Nuhn P; Tully K; Roghmann F; Bolenz C; Zengerling F; Wirtz RM; Muders M; Kristiansen G; Bald T; Ellinger J; Wullich B; Hölzel M; Hartmann A; Erben P; Ritter M; Eckstein M
Eur J Cancer; 2022 May; 167():13-22. PubMed ID: 35366569
[TBL] [Abstract][Full Text] [Related]
2. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Klümper N; Saal J; Berner F; Lichtensteiger C; Wyss N; Heine A; Bauernfeind FG; Ellinger J; Brossart P; Diem S; Schmid S; Joerger M; Frueh M; Ritter M; Hölzel M; Flatz L; Bald T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292517
[TBL] [Abstract][Full Text] [Related]
3.
Klümper N; Wüst L; Saal J; Ralser DJ; Zarbl R; Jarczyk J; Breyer J; Sikic D; Wullich B; Bolenz C; Roghmann F; Hölzel M; Ritter M; Strieth S; Hartmann A; Erben P; Wirtz RM; Landsberg J; Dietrich D; Eckstein M
Oncoimmunology; 2023; 12(1):2267744. PubMed ID: 37868689
[TBL] [Abstract][Full Text] [Related]
4. Early C-reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma.
Qin Q; Kou X; Zheng Y; Zhou F; Zhang X; Liu H
J Hepatocell Carcinoma; 2023; 10():2009-2019. PubMed ID: 37954495
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma.
Klümper N; Schmucker P; Hahn O; Höh B; Mattigk A; Banek S; Ellinger J; Heinzelbecker J; Sikic D; Eckstein M; Strauß A; Zengerling F; Hölzel M; Zeuschner P; Kalogirou C
Clin Transl Immunology; 2021; 10(12):e1358. PubMed ID: 34925829
[TBL] [Abstract][Full Text] [Related]
6. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
[TBL] [Abstract][Full Text] [Related]
7. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA; Moik F; Steinlechner S; Posch F; Mayer MC; Sandner AM; Berton F; Schlintl V; Koch L; John N; Wurm R; Pichler M; Bauernhofer T; Reimann P; Wohlkönig C; Richtig E; Winder T; Preusser M; Jost PJ; Ay C; Gerger A; Terbuch A; Riedl JM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097343
[TBL] [Abstract][Full Text] [Related]
8. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G;
JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479
[TBL] [Abstract][Full Text] [Related]
9. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
10. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
[TBL] [Abstract][Full Text] [Related]
11. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma.
Kött J; Zimmermann N; Zell T; Heidrich I; Geidel G; Rünger A; Smit DJ; Merkle M; Parnian N; Hansen I; Hoehne I; Abeck F; Torster L; Weichenthal M; Pantel K; Schneider SW; Gebhardt C
J Eur Acad Dermatol Venereol; 2024 Mar; ():. PubMed ID: 38466133
[TBL] [Abstract][Full Text] [Related]
13. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
[TBL] [Abstract][Full Text] [Related]
14. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
15. Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.
Tomisaki I; Harada M; Tokutsu K; Minato A; Nagata Y; Kimuro R; Matsumoto M; Fujimoto N
In Vivo; 2021; 35(6):3563-3568. PubMed ID: 34697195
[TBL] [Abstract][Full Text] [Related]
16. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
[TBL] [Abstract][Full Text] [Related]
17. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.
Alessandrino F; Gujrathi R; Nassar AH; Alzaghal A; Ravi A; McGregor B; Sonpavde G; Shinagare AB
Eur Urol Oncol; 2020 Oct; 3(5):680-686. PubMed ID: 31412003
[TBL] [Abstract][Full Text] [Related]
18. Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial.
Saal J; Bald T; Eckstein M; Ritter M; Brossart P; Ellinger J; Hölzel M; Klümper N
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 37004206
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
[TBL] [Abstract][Full Text] [Related]
20. A robust gene prognostic index composed of GZMB, IRF1, and TP63 can stratify the risk of two metastatic urothelial carcinoma cohorts based on immune checkpoint blockade therapy.
Lin J; Ding M; Qin C; Song Y; Yang W; Du Y; Xu T
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9877-9890. PubMed ID: 37247083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
